Remove Gene Editing Remove Life Science Remove Protein Remove Reagent
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. This ensures that gene therapy payloads can be targeted to the desired tissue and internalised into the target cell to deliver functional payloads.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.

article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Current research is focused on designing CRISPR-enhanced CAR T cells that are resistant to immunosuppressive cytokines such as transforming growth factor-β (TGF-β) 2 , programmed cell death protein (PD-1) 3 , or other negative T cell regulators 4 (CTLA-4, LAG-3, and TIM-3), thus improving anti-tumour functions.

DNA 98